The trademark application DHANLYRA was filed by Kiniksa Pharmaceuticals, GmbH, a corporation established under the laws of the Swiss Confederation (the "Applicant"). The application was published for oppositions on November 3, 2025, and still open for oppositions.
The application was filed in English (German was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Anti-inflammatories
Cardiovascular pharmaceuticals
Pharmaceutical preparations for the prevention and treatment of inflammatory diseases and disorders
Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders
Pharmaceutical preparations for the prevention and treatment of cardiac diseases and disorders
Pharmaceutical preparations for the prevention and treatment of immune-mediated diseases and disorders
Pharmaceutical preparations for the prevention and treatment of rare diseases and disorders.